View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 11, 2018

Deals this week: MannKind, XtalPi, Ascendia Pharmaceuticals

Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug, Afrezza.

Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug, Afrezza.

MannKind will supply the FDA-approved drug to Cipla for distribution and marketing in India as part of the agreement.

Cipla will make an upfront payment of $2.2m to MannKind within one month of signing the agreement. It will also make additional regulatory milestone payments, as well as royalties from sales of Afrezza India to MannKind.

US-based computation-driven pharmaceutical technology company XtalPi has signed a research collaboration agreement with Pfizer.

The two companies will collaborate to develop hybrid physics and an artificial intelligence (AI)-powered software platform, which will be helpful to find accurate molecular modelling of drug-like small molecules.

The collaboration builds on the existing association between the two companies on crystal structure prediction (CSP).

“Ascendia Pharmaceuticals has agreed to collaborate with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines.”

Ascendia Pharmaceuticals has agreed to collaborate with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines.

Based in the US, Ascendia Pharmaceuticals develops formulations of existing drugs and facilitates formulations for pre-clinical and clinical stage products, while KC Pharmaceuticals, also based in the US, is a producer and distributor of private-label over-the-counter eye care, contact lens care, anti-diarrhoea, and nasal spray products.

Lannett Company has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International.

The product portfolio includes oral solutions with a few semi-solid products.

Lannett will pay an upfront payment and future milestone payments to the subsidiary as part of the agreement.

Based in the US, Lannett Company is a developer, manufacturer, packager and distributor of generic pharmaceutical products, while Endo International is a generics and specialist branded pharmaceutical company.

The acquisition will enable Lannett to diversify its product offering.

Endo International has appointed Bourne Partners as the lead financial adviser for the transaction.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU